Zbigniew Zuber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2193963/publications.pdf

Version: 2024-02-01

31	1,433	687220	477173
papers	citations	h-index	g-index
31	31	31	1779
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2385-2395.	13.9	716
2	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 2015, 74, 1110-1117.	0.5	251
3	Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Annals of the Rheumatic Diseases, 2014, 73, 1114-1122.	0.5	106
4	Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatric Rheumatology, 2017, 15, 86.	0.9	64
5	Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Research and Therapy, 2019, 21, 125.	1.6	31
6	Effect of rapid cessation of enzyme replacement therapy: A report of 5 cases and a review of the literature. Molecular Genetics and Metabolism, 2012, 107, 508-512.	0.5	26
7	Mucopolysaccharidosis type II in females and response to enzyme replacement therapy. American Journal of Medical Genetics, Part A, 2012, 158A, 450-454.	0.7	26
8	Etanercept treatment in juvenile idiopathic arthritis: The Polish registry. Medical Science Monitor, 2011, 17, SR35-SR42.	0.5	23
9	Role of Microparticles in the Pathogenesis of Inflammatory Joint Diseases. International Journal of Molecular Sciences, 2019, 20, 5453.	1.8	20
10	Physician Adherence to Treat-to-Target and Practice Guidelines in Rheumatoid Arthritis. Journal of Clinical Medicine, 2019, 8, 1416.	1.0	16
11	Efficacy and Safety of Tocilizumab for Polyarticularâ€Course Juvenile Idiopathic Arthritis in the Openâ€Label Twoâ€Year Extension of a Phase III Trial. Arthritis and Rheumatology, 2021, 73, 530-541.	2.9	16
12	Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis. Reumatologia, 2015, 53, 125-130.	0.5	15
13	The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II. PLoS ONE, 2014, 9, e85074.	1.1	14
14	Cervical Spine MRI Findings in Patients with Mucopolysaccharidosis Type II. Pediatric Neurosurgery, 2015, 50, 26-30.	0.4	13
15	Establishing percentile charts for hip joint capsule and synovial cavity thickness in apparently healthy children. Pediatric Rheumatology, 2017, 15, 8.	0.9	13
16	Pachydermodactyly – a report of two cases. Reumatologia, 2016, 54, 136-140.	0.5	12
17	Can Macrosomia or Large for Gestational Age Be Predictive of Mucopolysaccharidosis Type I, II and VI?. Pediatrics and Neonatology, 2016, 57, 181-187.	0.3	12
18	Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis. Reumatologia, 2016, 54, 19-23.	0.5	10

#	Article	lF	CITATIONS
19	Quiz Correct answer to the quiz. check your diagnosis Granulomatous pigmented purpura in an adolescent girl: a precursor of mycosis fungoides?. Polish Journal of Pathology, 2013, 2, 157-159.	0.1	8
20	Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial. Clinical Rheumatology, 2018, 37, 1807-1816.	1.0	8
21	Ultrasonographic Features of Hip Joints in Mucopolysaccharidoses Type I and II. PLoS ONE, 2015, 10, e0123792.	1.1	7
22	Oligoarticular onset juvenile idiopathic arthritis as the most common cause of disability of children and young adults. Reumatologia, 2019, 57, 189-191.	0.5	5
23	Ultrasound Evaluation of the Effectiveness of the Use of Acitretin in the Treatment of Nail Psoriasis. Journal of Clinical Medicine, 2021, 10, 2122.	1.0	5
24	A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study. Arthritis and Rheumatology, 2014, 66, S80-S81.	2.9	4
25	A case of mucopolysaccharidosis type VI in a polish family. Importance of genetic testing and genotype-phenotype relationship in the diagnosis of mucopolysaccharidosis. Molecular Genetics and Metabolism Reports, 2020, 25, 100658.	0.4	3
26	Effectiveness of subcutaneously administered methotrexate in patients with rheumatoid arthritis. Advances in Clinical and Experimental Medicine, 2019, 28, 1229-1235.	0.6	3
27	Role of Distinct Macrophage Populations in the Development of Heart Failure in Macrophage Activation Syndrome. International Journal of Molecular Sciences, 2022, 23, 2433.	1.8	3
28	Psoriasis and systemic lupus erythematosus in children – literature review based on case report. Reumatologia, 2020, 58, 48-55.	0.5	2
29	Cutaneous polyarteritis nodosa in a 7-year-old boy: difficulties in diagnosis. Reumatologia, 2019, 57, 301-305.	0.5	1
30	Comment on the article "Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatologyâ€. Reumatologia, 2018, 56, 409-409.	0.5	0
31	A nine-year-old patient affected by chromosomal aberration with the suspicion of juvenile idiopathic arthritis. Reumatologia, 2018, 56, 59-62.	0.5	О